CKD Prediction in HIV+ Patients
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–5
- Moderate Risk5–15
- High Risk15–100
The CKD Prediction in HIV+ Patients calculates estimating glomerular filtration rate (eGFR), staging renal disease, and adjusting drug clearances. Key inputs include age category. Scores guide adjusting renal medication clearance, coordinating nephrology follow-up, or planning renal replacement therapy. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Determines likelihood of HIV patients developing CKD in the next 5 years, whether they take tenofovir or not
Clinical Indication
The CKD Prediction in HIV+ Patients is indicated for bedside clinical practice to support Determines likelihood of HIV patients developing CKD in the next 5 years, whether they take tenofovir or not. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with acute kidney injury (AKI), chronic kidney disease stages 1-5, or acid-base and fluid-electrolyte disturbances. Clinical application is indicated across Nephrology clinics, hemodialysis units, acute inpatient renal services, and metabolic wards.
Limitations & Contraindications
eGFR estimation equations assume steady-state serum creatinine and become unreliable during unstable AKI, amputations, or extremes of muscle mass.
Clinical Pearls & Action Plan
Serum creatinine lags behind acute reductions in glomerular filtration; monitor hourly urine output and consider cystatin C in evolving AKI. Guideline pearl: Regular monitoring of kidney function recommended regardless of risk score.
Sum of risk factor points: Age (0-6) + Glucose >140 (2) + SBP >140 (1) + Hypertension (2) + Triglycerides >200 (1) + Proteinuria (2) + CD4+ <200 (1). 5-year CKD risk based on total score and tenofovir use status.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age_category | string | Yes | Patient age category(years) |
| glucose_elevated | string | Yes | Glucose > 140 mg/dL(mg/dL) |
| systolic_bp_elevated | string | Yes | Systolic blood pressure > 140 mmHg(mmHg) |
| hypertension | string | Yes | Diagnosis of hypertension |
| triglycerides_elevated | string | Yes | Triglycerides > 200 mg/dL(mg/dL) |
| proteinuria | string | Yes | Presence of proteinuria |
| cd4_low | string | Yes | CD4+ count < 200 cells/µL(cells/µL) |
| tenofovir_use | string | Yes | Current or planned tenofovir (TDF) use |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–5 | Low Risk | Low risk for CKD development |
| 5–15 | Moderate Risk | Moderate risk for CKD development |
| 15–100 | High Risk | High risk for CKD development |
Evidence-Based References (EBM)
- Scherzer R, Gandhi M, Estrella MM, Tien PC, Deeks SG, Grunfeld C, Peralta CA, Shlipak MG. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. AIDS. 2014;28(9):1289-95.
- Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D Study Group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015;12(3):e1001809.